



PATENT

Client-Matter No.: 66872-029
(P-AR 5747)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Liang and Woodward

Serial No.: 10/689,861

Filed: October 20, 2003

For: HUMAN PROSTAGLANDIN
DP RECEPTOR VARIANTS AND
METHODS OF USING SAME

) Confirmation No.: 3763

) Group Art Unit: Unknown

) Examiner: Unknown

) I hereby certify that this correspondence is being
) deposited with the United States Postal Service as first
) class mail in an envelope addressed to: Commissioner
) for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
) on March 31, 2004.

) By: Andrea L. Gashler
) Andrea L. Gashler, Reg. No. 41,029

) March 31, 2004
) Date of Signature

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449, and a copy of each is enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and that their consideration be made of written record in the application file.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 502624.


Respectfully submitted,

Date: March 31, 2004

Andrea L. Gashler

Andrea L. Gashler
Registration No.: 41,029
Telephone: (858) 535-9001
Facsimile: (858) 535-8949

McDERMOTT, WILL & EMERY
4370 La Jolla Village Drive, Suite 700
San Diego, California 92122



In re Application of)
Liang and Woodward)
Serial No.: 10/689,861)
Filed: October 20, 2003)
For: HUMAN PROSTAGLANDIN)
DP RECEPTOR VARIANTS AND)
METHODS OF USING SAME)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 31, 2004.

March 31, 2004
Date of Signature

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449, and a copy of each is enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and that their consideration be made of written record in the application file.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 502624.

Respectfully submitted,

Date: March 31, 2004

Andrea R. Hasler

Andrea L. Gashler
Registration No.: 41,029
Telephone: (858) 535-9001
Facsimile: (858) 535-8949

McDERMOTT, WILL & EMERY
4370 La Jolla Village Drive, Suite 700
San Diego, California 92122

Form PTO 1473 U.S. Department of Commerce Patent and Trademark Office	ATTY CLIENT- MATTER NO: 66872-029 (P-AR 5747)	SERIAL NO. 10/689,861
APR 02 2004 PATENT AND TRADEMARK OFFICE	APPLICANT: Liang and Woodward	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: October 20, 2003	GROUP: Unknown CONFIRMATION NO.: 3763

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	5,093,329	03/03/1992	David A. Woodward	514	469	03/12/1990

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	Genbank Accession No. NM_000953, Homo sapiens prostaglandin D2 receptor (DP) (PTGDR), mRNA.
	Genbank Accession No. AL365475, Human chromosome 14 DNA sequence BAC R-452D12 of library RPCI-11 from chromosome 14 of Homo sapiens (Human), complete sequence.
	Boie et al., "Molecular Cloning and Characterization of the Human Prostanoid DP Receptor," <u>J. Biol. Chem.</u> 270:18190-18916 (1995).
	Breyer et al., "Prostanoid Receptors: Subtypes and Signaling," <u>Ann. Rev. Pharm. Toxicol.</u> 41:661-690 (2001).
	Coleman et al., "VIII. International Union of Pharmacology Classification of Prostanoid Receptors: Properties, Distribution, and Structure of the Receptors and Their Subtypes," <u>Pharm. Rev.</u> 46(2):205-229 (1994).
	Escribano et al., "cDNA from human ocular ciliary epithelium homologous to β ig-h3 is preferentially expressed as an extracellular protein in the corneal epithelium," <u>J. Cell. Physiol.</u> 160:511-521 (1994).
	Giles et al., "The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist," <u>Br. J. Pharm.</u> 96(2):291-300 (1989).
	Hayaishi, "Molecular mechanisms of sleep-wake regulation: A role of prostaglandin D2," <u>Phil. Trans. R. Soc. Lond. B.</u> 355:275-280 (2000).
	Hirata et al., "Molecular Characterization of a Mouse Prostaglandin D Receptor and Functional Expression of the Cloned Gene," <u>Proc. Natl. Acad. Sci. USA</u> 91:11192-11196 (1994).
	Kobayashi and Narumiya, "Function of prostanoid receptors: Studies on knockout mice," <u>Prostaglandins and other Lipid Mediators</u> 68-69:557-573 (2002).
	Oida et al., "Expression of messenger RNA for the prostaglandin D receptor in the leptomeninges of the mouse brain," <u>FEBS Lett.</u> 417:53-56 (1997).
	Pons et al., "Pro-inflammatory and anti-inflammatory effects of the stable prostaglandin D2 analogue, ZK 118.182," <u>Eur. J. Pharm.</u> 261:237-247 (1994).
	Woodward et al., "The Molecular Biology and Ocular Distribution of Prostanoid Receptors," <u>Survey of Ophthalm.</u> 41(2):S15-S21 (1997).
	Wright et al., "A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor," <u>Eur. J. Pharm.</u> 377:101-115 (1999).
	Wright et al., "Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist," <u>Br. J. Pharm.</u> 123:1317-1324 (1998).

Examiner:	Date Considered:
-----------	------------------